About

Retro Biosciences focuses on extending healthy human lifespan by developing therapeutics that target the cellular mechanisms of aging. The company works on three main programs: cellular reprogramming, plasma-inspired therapeutics, and autophagy, each at different stages of development. By addressing the root causes of age-related diseases, Retro Biosciences aims to reduce healthcare costs associated with these conditions. The company utilizes advanced technologies like single-cell multi-omics and computational biology to support its research. With $180 million in funding, Retro Biosciences is positioned to advance its therapeutic candidates towards clinical applications, ultimately aiming to improve health outcomes as people age.

Simplify's Take

What believers are saying

• Partnership with Multiply Labs could reduce costs and accelerate therapy market entry.
• Collaboration with OpenAI enhances stem cell production efficiency using AI models.
• Significant funding from Sam Altman supports long-term research and development goals.

What critics are saying

• Automated systems from Multiply Labs may not meet specific cell therapy needs.
• Pressure from significant investment may impact long-term strategic decisions.
• Ethical and regulatory challenges may arise from lifespan extension focus.

What makes Retro Biosciences unique

• Retro Biosciences targets cellular mechanisms of aging to extend lifespan by ten years.
• The company employs advanced technologies like single-cell multi-omics and computational biology.
• Retro Biosciences has a diversified pipeline with programs in cellular reprogramming and autophagy.

Help us improve and share your feedback! Did you find this helpful?

YesNo